In a small study, proteinuria improved even in patients with nephrotic syndrome and lupus nephritis. Belimumab appears similarly effective and well tolerated in patients with lupus nephritis (LN) with ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro ...

A groundbreaking study, presented today at the 61st ERA Congress, has uncovered a significant breakthrough in the diagnosis and monitoring of kidney diseases associated with nephrotic syndrome. Using ...

Objective: To develop better therapy mode and reduce the rate of relapse of nephrotic syndrome in children with steroid sensitive nephrotic syndrome (SSNS). Methods: Compared the effect of 2-month ...

Roche RHHBY announced that the FDA has approved a regulatory filing seeking the label expansion of Gazyva/Gazyvaro ...

Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study2 Lupus nephritis is a debilitating condition that ...

Basel: Roche has announced that the US Food and Drug Administration (FDA) has approved Gazyva/Gazyvaro (obinutuzumab) for the ...

FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...